An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will announce its first quarter 2024 financial results on May 7, 2024. The company focuses on developing drug candidates for immuno-inflammatory diseases. A conference call will follow to provide a corporate update.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) annuncerà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024. La compagnia è focalizzata sullo sviluppo di candidati farmaceutici per malattie immuno-infiammatorie. Seguirà una teleconferenza per fornire un aggiornamento aziendale.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) anunciará sus resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024. La empresa se centra en el desarrollo de candidatos a medicamentos para enfermedades inmuno-inflamatorias. Una conferencia telefónica seguirá para proporcionar una actualización corporativa.
Aclaris Therapeutics, Inc. (나스닥: ACRS)는 2024년 5월 7일에 2024년 1분기 재정 결과를 발표할 예정입니다. 이 회사는 면역염증 질환을 위한 약물 후보를 개발하는 데 중점을 둡니다. 이어서 기업 업데이트를 제공하는 컨퍼런스 콜이 있을 예정입니다.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) annoncera ses résultats financiers pour le premier trimestre 2024 le 7 mai 2024. L'entreprise se concentre sur le développement de candidats médicaments pour les maladies immuno-inflammatoires. Une conférence téléphonique suivra pour fournir une mise à jour de l'entreprise.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) wird am 7. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen konzentriert sich auf die Entwicklung von Arzneimittelkandidaten für immuno-entzündliche Krankheiten. Im Anschluss wird eine Telefonkonferenz stattfinden, um ein Unternehmensupdate zu geben.
Positive
None.
Negative
None.
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets.
Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The conference call will be webcast live over the internet and can be accessed by logging into the “Investors” page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
